FMP
AN2 Therapeutics, Inc.
ANTX
NASDAQ
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
2.48 USD
0.01 (0.403%)
About
ceo
Mr. Eric E. Easom
sector
Healthcare
industry
Biotechnology
website
https://www.an2therapeutics.com
exchange
NASDAQ
Description
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
CIK
0001880438
ISIN
US0373261058
CUSIP
037326105
Address
1800 El Camino Real
Phone
650-331-9090
Country
US
Employee
41
IPO Date
Mar 25, 2022
Key Executives
